{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T14:42:10Z","timestamp":1695998530233},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":203,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><\/jats:sec><jats:sec><jats:title>Background.<\/jats:title><jats:p>Data submitted to the FDA were reviewed to analyze the relationship between <jats:italic>Helicobacter pylori<\/jats:italic> infection and the incidence of early duodenal ulcers, within 6\u00a0weeks, following treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods.<\/jats:title><jats:p>Retrospective analyzes were performed on data from three <jats:italic>H.\u00a0pylori<\/jats:italic> development programs submitted to the FDA: ranitidine\u2010bismuth\u2010citrate (RBC), lansoprazole (L) and omeprazole (O). Efficacy assessments for the RBC, L and O programs were made at end of a 4\u2010week treatment period, 4\u20136\u00a0weeks following the end of a 14\u2010day treatment period, and 4\u00a0weeks following the end of a 4\u2010week treatment period, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Overall, there was a 15%, 21% and 23% decrease in the number of patients in the RBC, L and O programs, respectively, with ulcers among <jats:italic>H.\u00a0pylori<\/jats:italic> cleared\/eradicated patients post\u2010treatment compared with patients with persistent infection. Among patients who did not have cleared\/eradicated <jats:italic>H.\u00a0pylori<\/jats:italic> in the RBC and O programs, where antisecretory agents were continued beyond the antimicrobial treatment period, the number of ulcers was lower in the antisecretory plus antimicrobial subgroups compared with the antimicrobial alone subgroups (37% vs. 46% for RBC and 33% vs. 42% for O). Among patients with cleared\/eradicated <jats:italic>H.\u00a0pylori<\/jats:italic>, the number of patients with ulcers in the antimicrobial alone subgroups and antisecretory plus antimicrobial subgroups were similar within each program. Antimicrobials alone had significantly lower rates of ulcers among patients with cleared\/eradicated <jats:italic>H.\u00a0pylori<\/jats:italic> as compared with patients without clearance\/eradication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>The early incidence of duodenal ulcers is significantly decreased in patients with <jats:italic>H.\u00a0pylori<\/jats:italic> clearance\/eradication.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1523-5378.2001.00013.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:22:30Z","timestamp":1047424950000},"page":"84-92","source":"Crossref","is-referenced-by-count":4,"title":["<i>Helicobacter pylori<\/i> and Early Duodenal Ulcer Status Post\u2010Treatment: a Review"],"prefix":"10.1111","volume":"6","author":[{"given":"Joette M.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy P.","family":"Silliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl A.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy Y.","family":"Siepman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Sugg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520010077036"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8613015"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.40182000.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00333.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.1.43"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)80026-1"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.1998.08016.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0953-0673.1996.00251.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.1998.08050.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"A64","DOI":"10.1016\/0016-5085(95)22920-5","article-title":"GR122311X (ranitidine bismuth citrate) with amoxycillin for the treatment of duodenal ulcer (Abstract","volume":"108","author":"Butruk E","year":"1995","journal-title":"Gastroenterology"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.2.181"},{"key":"e_1_2_5_13_2","first-page":"A165","article-title":"GR122311X (ranitidine bismuth citrate) with amoxycillin for the eradication of Helicobacter pylori (Abstract","volume":"37","author":"O'Morain C","year":"1995","journal-title":"Gut"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1997.tb00074.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00046.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.169_b.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.15.1651"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00303.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00602.x"},{"key":"e_1_2_5_20_2","unstructured":"Division of Anti\u2010Infective Drug Products (DAIDP) Points to Consider. March. Addendum Draft (June 1995 Revision) Helicobacter pylori\u2010associated peptic ulcer disease Indication #25 .http:\/\/www.fda.gov\/cder\/guidance\/ptc.htm. 1995."},{"key":"e_1_2_5_21_2","first-page":"A117","article-title":"Gastric cytoprotection by clarithromycin in the rat (Abstract","volume":"106","author":"Lai KC","year":"1994","journal-title":"Gastroenterology"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1994.tb01284.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)22949-3"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91006-8"},{"key":"e_1_2_5_25_2","first-page":"276","article-title":"Furazolidone in peptic ulcer (letter","author":"Zhao HY","year":"1985","journal-title":"Lancet"},{"key":"e_1_2_5_26_2","first-page":"1048","article-title":"Double\u2010blind short\u2010term trial of furazolidone in peptic ulcer (letter","author":"Zheng ZT","year":"1985","journal-title":"Lancet"},{"key":"e_1_2_5_27_2","first-page":"A5","article-title":"Dual therapy of clarithromycin and omeprazole for treatment of patients with duodenal ulcers associated with H. pylori infection (Abstract","volume":"37","author":"Hunt R","year":"1995","journal-title":"Gut"},{"key":"e_1_2_5_28_2","unstructured":"FangG XiaZ LiY.Therapeutic effect of amoxicillin on duodenal ulcer (Abstract). World Congress of Gastroenterology. Los Angeles CA USA:15P 1994."}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1523-5378.2001.00013.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.2001.00013.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T10:41:54Z","timestamp":1695897714000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1523-5378.2001.00013.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1046\/j.1523-5378.2001.00013.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-5378.2001.00013.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}